Paper ID: 2404.02348

COVID-19 Detection Based on Blood Test Parameters using Various Artificial Intelligence Methods

Kavian Khanjani, Seyed Rasoul Hosseini, Hamid Taheri, Shahrzad Shashaani, Mohammad Teshnehlab

In 2019, the world faced a new challenge: a COVID-19 disease caused by the novel coronavirus, SARS-CoV-2. The virus rapidly spread across the globe, leading to a high rate of mortality, which prompted health organizations to take measures to control its transmission. Early disease detection is crucial in the treatment process, and computer-based automatic detection systems have been developed to aid in this effort. These systems often rely on artificial intelligence (AI) approaches such as machine learning, neural networks, fuzzy systems, and deep learning to classify diseases. This study aimed to differentiate COVID-19 patients from others using self-categorizing classifiers and employing various AI methods. This study used two datasets: the blood test samples and radiography images. The best results for the blood test samples obtained from San Raphael Hospital, which include two classes of individuals, those with COVID-19 and those with non-COVID diseases, were achieved through the use of the Ensemble method (a combination of a neural network and two machines learning methods). The results showed that this approach for COVID-19 diagnosis is cost-effective and provides results in a shorter amount of time than other methods. The proposed model achieved an accuracy of 94.09% on the dataset used. Secondly, the radiographic images were divided into four classes: normal, viral pneumonia, ground glass opacity, and COVID-19 infection. These were used for segmentation and classification. The lung lobes were extracted from the images and then categorized into specific classes. We achieved an accuracy of 91.1% on the image dataset. Generally, this study highlights the potential of AI in detecting and managing COVID-19 and underscores the importance of continued research and development in this field.

Submitted: Apr 2, 2024